vTv Therapeutics Inc. (NASDAQ: VTVT)

VTv Therapeutics Inc., often recognized by its stock symbol VTVT, is a company that operates within the biopharmaceutical industry. The organization is dedicated to the development of orally administered treatments for metabolic and inflammatory diseases, with a primary focus on type 1 diabetes (T1D) and other metabolic disorders.

The company's main business activities revolve around the development of small molecule drug candidates. Their primary product, cadisegliatin (TTP399), is a novel, orally administered, small molecule, liver-selective glucokinase activator (GKA) designed for the treatment of T1D. This drug has demonstrated promising results in clinical trials, showing a statistically significant improvement in HbA1c and a clinically meaningful decrease in the frequency of severe and symptomatic hypoglycemia.

VTv Therapeutics has a competitive advantage in the development of orally administered treatments for T1D, particularly with cadisegliatin. The company's liver-selective GKA approach offers a unique mechanism of action that may improve glucose control and reduce the risk of hypoglycemia. Key competitors in this space include established players such as Eli Lilly and Company, Novo Nordisk A/S, and Sanofi, all of which have a strong presence in the diabetes market and a range of approved products for T1D treatment.

In addition to cadisegliatin, the company has other pipeline candidates. These include TTP273, a GLP-1 receptor agonist (GLP-1RA) for the treatment of cystic fibrosis related diabetes (CFRD). The company is currently exploring options to study the therapeutic potential of TTP273 in patients with CFRD.

VTv Therapeutics generates revenue through the development and commercialization of its proprietary drug candidates. The company has raised funds through the sale of its common stock and the issuance of warrants, and has also received funding from collaborations and license agreements. For instance, they have a collaboration agreement with G42 Investments AI Holding RSC Ltd. to develop and commercialize cadisegliatin in the Middle East region.

The company's product portfolio includes cadisegliatin (TTP399), a novel, orally administered, small molecule, liver-selective glucokinase activator (GKA) for the treatment of T1D, and TTP273, a GLP-1 receptor agonist (GLP-1RA) for the treatment of cystic fibrosis related diabetes (CFRD). The company is also developing HPP737, a PDE4 inhibitor for the treatment of inflammatory lung diseases, in partnership with Newsoara Biopharma, and azeliragon, a PDE4 inhibitor for the treatment of glioblastoma and other inflammatory lung diseases, in partnership with Cantex Pharmaceuticals, Inc.